Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Diabetologia 2001; 44(3):298-304D

Abstract

AIMS/HYPOTHESIS

To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus.

METHODS

Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects.

RESULTS

Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%).

CONCLUSIONS/INTERPRETATION

As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike.

Authors+Show Affiliations

Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford OX3 7LF, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11317659

Citation

Clarke, P, et al. "Cost-effectiveness Analysis of Intensive Blood-glucose Control With Metformin in Overweight Patients With Type II Diabetes (UKPDS No. 51)." Diabetologia, vol. 44, no. 3, 2001, pp. 298-304.
Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001;44(3):298-304.
Clarke, P., Gray, A., Adler, A., Stevens, R., Raikou, M., Cull, C., ... Holman, R. (2001). Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia, 44(3), pp. 298-304.
Clarke P, et al. Cost-effectiveness Analysis of Intensive Blood-glucose Control With Metformin in Overweight Patients With Type II Diabetes (UKPDS No. 51). Diabetologia. 2001;44(3):298-304. PubMed PMID: 11317659.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). AU - Clarke,P, AU - Gray,A, AU - Adler,A, AU - Stevens,R, AU - Raikou,M, AU - Cull,C, AU - Stratton,I, AU - Holman,R, AU - ,, PY - 2001/4/25/pubmed PY - 2001/8/24/medline PY - 2001/4/25/entrez SP - 298 EP - 304 JF - Diabetologia JO - Diabetologia VL - 44 IS - 3 N2 - AIMS/HYPOTHESIS: To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. METHODS: Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight (> 120% ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. RESULTS: Intensive blood-glucose control with metformin produced a net saving of 258 Pounds per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6%). CONCLUSIONS/INTERPRETATION: As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike. SN - 0012-186X UR - https://www.unboundmedicine.com/medline/citation/11317659/Cost_effectiveness_analysis_of_intensive_blood_glucose_control_with_metformin_in_overweight_patients_with_type_II_diabetes__UKPDS_No__51__ L2 - https://dx.doi.org/10.1007/s001250051617 DB - PRIME DP - Unbound Medicine ER -